Evelo Biosciences (EVLO) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year price objectives for Evelo Biosciences' shares. Their EVLO share price forecasts range from $2.00 to $5.00. On average, they predict the company's share price to reach $3.17 in the next year. This suggests a possible upside of 1,991.6% from the stock's current price.
View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts.

Evelo Biosciences' stock was trading at $1.61 on January 1st, 2023. Since then, EVLO shares have decreased by 90.6% and is now trading at $0.1514.
View the best growth stocks for 2023 here.

Evelo Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,570,000 shares, an increase of 58.7% from the April 30th total of 2,250,000 shares. Based on an average daily trading volume, of 3,620,000 shares, the short-interest ratio is presently 1.0 days.
View Evelo Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 1st 2023.
View our EVLO earnings forecast.

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Evelo Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.60%), BlackRock Inc. (1.04%), CVI Holdings LLC (0.76%), Susquehanna International Group LLP (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David R Epstein, Duncan Mchale, Marella Thorell, Simba Gill, Stephen J Carriere, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends.

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVLO stock can currently be purchased for approximately $0.15.

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $16.96 million. The company earns $-114,530,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

The company employs 122 workers across the globe.

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.